本文選題：血管性癡呆 + 聯(lián)合用藥��； 參考：《蘭州大學(xué)》2014年碩士論文

【摘要】：目的：對(duì)比探討膽堿酯酶抑制劑聯(lián)合谷氨酸受體拮抗劑、降血脂藥三聯(lián)療法治療血管性癡呆的臨床療效及安全評(píng)估。 方法：將湖南省湘西自治州精神病醫(yī)院康復(fù)中心2010年3月—2013年3月先后收治的60例血管性癡呆患者按用藥不同分為對(duì)照組和治療組各30例,其中治療組在基礎(chǔ)用藥的基礎(chǔ)上加用美金剛、阿托伐他汀和多奈哌齊；對(duì)照組加用多奈哌齊。兩組共治療6個(gè)月。兩組治療前后分別用簡(jiǎn)易精神認(rèn)知量表(MMSE)、行為量表(Blessed-Roth)、日常生活能力量表(ADL)評(píng)定療效；用藥物副反應(yīng)量表(TESS),相關(guān)實(shí)驗(yàn)室檢查如血、尿、糞常規(guī),心電圖,肝、腎功能,電解質(zhì)等指標(biāo)評(píng)定用藥安全性。 結(jié)果：治療后治療組MMSE評(píng)分較對(duì)照組升高,ADL和Blessed-Roth評(píng)分較對(duì)照組降低,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。治療組總有效率較對(duì)照組高(83.3%和53.3%),差異有統(tǒng)計(jì)學(xué)意義(x2=6.239,P0.05)。兩組治療后TESS評(píng)分比較差異無(wú)統(tǒng)計(jì)學(xué)意義(PO.05)。 結(jié)論：膽堿酯酶抑制劑聯(lián)合谷氨酸受體拮抗劑、降血脂藥三聯(lián)用藥治療血管性癡呆可以顯著提高臨床療效,且聯(lián)合用藥不會(huì)影響其安全性。
[Abstract]:Objective: to evaluate the clinical efficacy and safety of cholinesterase inhibitor combined with glutamate receptor antagonist and antilipidemic drugs in the treatment of vascular dementia. Methods: sixty patients with vascular dementia were divided into control group (n = 30) and treatment group (n = 30) according to their medication from March 2010 to March 2013 in the Rehabilitation Center of Xiangxi Autonomous Prefecture Psychiatric Hospital of Hunan Province. The treatment group was treated with Atto vastatin and Donepezil on the basis of basic medication, while the control group with Donepezil. The two groups were treated for 6 months. Before and after treatment, the two groups were evaluated with MMSEN, Blessed-Rothia, ADL, and TESS with the drug side effects scale, including blood, urine, faecal routine, electrocardiogram, liver and kidney function. Electrolyte and other indicators were used to evaluate the safety of drug use. Results: after treatment, the MMSE scores in the treatment group were significantly higher than those in the control group, and the Blessed-Roth scores were significantly lower than those in the control group (P 0.05). The total effective rate of the treatment group was 83.3% and 53.3% higher than that of the control group, and the difference was statistically significant. There was no significant difference in TESS score between the two groups after treatment. Conclusion: cholinesterase inhibitor combined with glutamate receptor antagonist and triplex antilipidemic drugs can significantly improve the clinical efficacy of vascular dementia and its safety will not be affected by the combination of cholinesterase inhibitor and glutamate receptor antagonist.
【學(xué)位授予單位】：蘭州大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R749.13

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 傅仁杰;腦血管性癡呆的辨證與治療經(jīng)驗(yàn)[J];北京中醫(yī);1988年05期

2 趙福順,韓臣子;復(fù)合法治療腦血管性癡呆30例[J];北京中醫(yī);1992年04期

3 鄧振明,袁應(yīng)堅(jiān);中風(fēng)癡呆病[J];中國(guó)醫(yī)藥學(xué)報(bào);1991年03期

4 徐浩,馬苓云,晁民,邵念方;老年癡呆的中醫(yī)論治[J];中國(guó)醫(yī)藥學(xué)報(bào);1996年02期

5 姜宏;張秀清;;鹽酸多奈哌齊對(duì)血管性癡呆患者精神狀態(tài)和日常生活活動(dòng)能力的影響[J];中國(guó)醫(yī)藥科學(xué);2011年09期

6 李先慶,汪洋,張國(guó)印,關(guān)勇遙,范海斌;益智醒腦藥帽蒸氣浴療法治療腦血管性癡呆臨床療效觀察[J];湖北中醫(yī)雜志;1998年05期

7 馬云枝;血管性癡呆的論治[J];河南中醫(yī);2000年04期

8 田軍彪,王艷君,王石紅,蔡月花;強(qiáng)力增智飲對(duì)血管性癡呆患者血脂及血液流變學(xué)的影響[J];河北中醫(yī)藥學(xué)報(bào);2004年02期

9 姜建德,許振亞;血管性癡呆的辨治經(jīng)驗(yàn)[J];遼寧中醫(yī)雜志;2000年11期

10 劉泰,陸暉;血管性癡呆的中醫(yī)研究進(jìn)展[J];遼寧中醫(yī)雜志;2001年08期

，

本文編號(hào)：1940115